Incidence

Mapping the Potential Risk of Mycetoma Infection in Sudan and South Sudan Using Ecological Niche Modeling

What is the potential distribution of mycetoma in Sudan and South Sudan? What are the most important factors associated with the spatial distriutional patterns of disease cases in Both countries. 

 

Countries: Sudan
Diseases: Mycetoma

Understanding areas of increased trachoma risk (hotspots) through the implementation of a post validation trachoma surveillance strategy

To determine if there is evidence of on-going or recent transmission in the “hotspot” communities of increased risk two years after they were identified during the pre-validation surveys (clinical, antibody and infection data).

Countries: Ghana
Diseases: Trachoma

Lymphatic Filariasis Positive-Case Follow-up After TAS 2 in Haiti

To identify the sampling strategy for positive case follow-up after TAS 2 and TAS 3 that optimizes the chances of correctly identifying evidence of ongoing transmission, while saving program resources.

Countries: Haiti

Investigation of possible ongoing Schistosoma hybridization in Nigeria and implications for response to treatment

To investigate the presence and epidemiology of Schistosoma hybrids in Nigeria. The acquisition of new genes through hybridization may generate new phenotypes that might differ in virulence, drug resistance, pathology, and host use, ultimately leading to the emergence of new diseases. Hybrids can develop into a new emerging pathogen, necessitating new control strategies in zones where both parental species overlap, an intense and rapid control response is required to minimize further spread of the hybrid and possible escalation of human schistosomiasis.

Countries: Nigeria
Diseases: Schistosomiasis

Studies of Gene Expression Pattern of Glutathione-S-Transferase (OvGST1) in the host and vector Simulium damnosum s.l.

To study the glutathione-S-transferase (OvGST1) gene expression pattern in the life cycle stages critical for the establishment of infection by Onchocerca volvulus.

Countries: Nigeria
Diseases: Onchocerciasis

A-WOL Macrofilaricidal Drug Discovery

Deliver at least one novel pre-clinical candidate capable of delivering a macrofilaricide treatment for onchocerciasis (and lymphatic filariasis) within a seven-day treatment period or less.

Countries:

Optimizing and implementing A·WOL macrofilaricidal drugs and regimes

Establish the best registered drug for deployment as a macrofilaricide alone and/or in combination with standard anti-filarial drugs.

Countries:

AWOL Discovery Supplemental Award

Late lead optimisation

Countries:

Global Health Innovative Technology Fund (GHIT): 2014-2016 Anti-Wolbachia lead optimisation

Establish the most promising template for final lead optimization from a screen of >10000 compounds from the BioFocus library which revealed compounds with very good anti-Wolbachia activity.

Countries:

Pages